Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease
NCT07354880 on ClinicalTrials.gov · last registry update 2026-01-21
A small phase 4 — 30 participants, against a typical 75. Due to report 30 June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Change in exercise capacity after 6 months of treatment with tirzepatide. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2026-01-20
- Primary completion
- 2027-06-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in exercise capacity after 6 months of treatment with tirzepatide.
Conditions studied
Obesity & Overweight · Adult Congenital Heart Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.